Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada

This study demonstrates that, in comparison to voriconazole, isavuconazole is a cost-effective strategy for the treatment of patients with suspected IPA, regardless of their life expectancy.